NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on March 27, 2023. Total no. of equity shares bought back are 4600 NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on March 23, 2023. Total no. of equity shares bought back are 9000 NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on March 21, 2023. Total no. of equity shares bought back are 55000 NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of share Certificate NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
intimation for issue of duplicate share certificate NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares
Public Announcement for Buy-back of Shares
Natco launches additional strengths of generic version of Revlimid in US
Natco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multiple myeloma, in the US. The company has launched 2.5 mg, and 20 mg strengths of the generic version of Revlimid (lenalidomide capsules) through its marketing partner Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, Natco Pharma said in a regulatory filing. "With this launch the companies (have) made available all the strengths of lenalidomide in the US market," it added. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma, the filing said. NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO announces the Launch of additional strengths for the Generic Version of Revlimid(r) (lenalidomide capsules), in the USA NATCO PHARMA LTD. - 524816 - Board Resolution For Buy Back Of Equity Shares Of The Company
Board Resolution for Buy back of Equity Shares of the Company Natco Pharma board okays 210-cr buyback offer
To purchase at a maximum price of 700 a share from open market